Design, Synthesis, and Characterization of Novel Substituted 1,2,4-Triazines: Cytotoxic Activity on HepG2 and HT-29 Cell Lines, Enzyme Inhibition, and Molecular Docking Studies

dc.contributor.author Cetin, Adnan
dc.contributor.author Oguz, Ercan
dc.contributor.author Wolinska, Ewa
dc.contributor.author Rozbicki, Przemyslaw
dc.contributor.author Branowska, Danuta
dc.contributor.author Turkan, Fikret
dc.date.accessioned 2025-11-30T19:16:25Z
dc.date.available 2025-11-30T19:16:25Z
dc.date.issued 2025
dc.description.abstract 1,2,4-Triazines exhibit various pharmacological properties due to their strong biological activities, such as anticancer, anti-inflammatory, antimicrobial, antiviral, and antioxidant, and also occupy an important place in the pharmaceutical field. The tested compounds were synthesized and characterized. 1,2,4-Triazines were evaluated for their inhibitory and cytotoxicity effects on acetylcholinesterase (AChE), glutathione S-transferase (GST), human liver cancer cell line (HepG2), and human colorectal adenocarcinoma cell line (HT-29). 1,2,4-Triazines (3a-c, 5, 6, 10) were found to inhibit these enzymes with IC50 values ranging from 1.41 to 4.28 mu M for AChE and from 1.58 to 4.13 mu M for GST. 1,2,4-Triazine compounds were tested in range of 12.5-100 mu M concentrations against HepG2 and HT-29 cell lines. Among the 1,2,4-triazines tested, 10 was the most effective substance on HepG2 cells, especially at high doses, while 3b was effective on HT-29. Furthermore, molecular docking results indicated that the 1,2,4-triazines showed strong binding and stability at the active site of enzymes and selected proteins. 1,2,4-Triazines may serve as promising precursors for the design of potent enzyme inhibitors and anticancer agents. en_US
dc.description.sponsorship Van Yuzuncu Yil University Scientific Research Projects Chairmanship (BAP) [TAP-2025-11628] en_US
dc.description.sponsorship This study was partly supported by the Van Yuzuncu Yil University Scientific Research Projects Chairmanship (BAP) (Project Number: TAP-2025-11628). en_US
dc.identifier.doi 10.1002/jbt.70591
dc.identifier.issn 1095-6670
dc.identifier.issn 1099-0461
dc.identifier.scopus 2-s2.0-105020992691
dc.identifier.uri https://doi.org/10.1002/jbt.70591
dc.identifier.uri https://hdl.handle.net/20.500.14720/29024
dc.language.iso en en_US
dc.publisher Wiley en_US
dc.relation.ispartof Journal of Biochemical and Molecular Toxicology en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Anticancer en_US
dc.subject Drug Discovery en_US
dc.subject Enzyme Inhibition en_US
dc.subject Spectroscopy en_US
dc.subject Triazine en_US
dc.title Design, Synthesis, and Characterization of Novel Substituted 1,2,4-Triazines: Cytotoxic Activity on HepG2 and HT-29 Cell Lines, Enzyme Inhibition, and Molecular Docking Studies en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.scopusid 24586619800
gdc.author.scopusid 57995137500
gdc.author.scopusid 6603316591
gdc.author.scopusid 57460249900
gdc.author.scopusid 55931796800
gdc.author.scopusid 57115336200
gdc.author.wosid Branowska, Danuta/Aaf-1187-2021
gdc.author.wosid Cetin, Adnan/Adp-4852-2022
gdc.coar.access metadata only access
gdc.coar.type text::journal::journal article
gdc.description.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
gdc.description.departmenttemp [Cetin, Adnan] Van Yuzuncu Yil Univ, Fac Educ, Dept Chem, Van, Turkiye; [Oguz, Ercan] Igdir Univ, Hlth Serv Vocat Sch, Dept Med Serv & Tech, Igdir, Turkiye; [Wolinska, Ewa; Rozbicki, Przemyslaw; Branowska, Danuta] Univ Siedlce, Inst Chem Sci, Siedlce, Poland; [Turkan, Fikret] Igdir Univ, Fac Dent, Dept Basic Sci, Igdir, Turkiye; [Turkan, Fikret] Nakhichevan State Univ, Med Fac, Dept Basic Med Sci, Nakhichevan, Azerbaijan en_US
gdc.description.issue 11 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q3
gdc.description.volume 39 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q2
gdc.identifier.pmid 41196635
gdc.identifier.wos WOS:001608895800001
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed

Files